Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00131924 · ClinicalTrials.gov registry record · Phase 2
High-Dose Esterified Estrogens in Treating Postmenopausal Women With Metastatic Breast Cancer That Has Failed Previous Hormone Therapy
A Phase 2 study, sponsored by Northwestern University.
- Terminated
- Registry status
- Phase 2
- Development phase
- 1
- Enrollment target
NCT00131924 is a Phase 2 study that was terminated before completion, run by Northwestern University. The registered enrollment target is 1 participants.
The verdict
NCT00131924, a Phase 2 study, was terminated before completion, sponsored by Northwestern University.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 1 participants
- Enrollment target
Study Summary
RATIONALE: High doses of esterified estrogens may stop the growth of breast cancer cells that no longer respond to hormone therapy. PURPOSE: This phase II trial is studying how well high-dose esterified estrogens work in treating postmenopausal women with metastatic breast cancer that has failed previous hormone therapy.
Interventions
- BIOLOGICAL esterified estrogens
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1 participants |
| Start Date | 2004-03 |
| Est. Completion | 2006-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00131924
The ClinicalTrials.gov registry entry for NCT00131924 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 1 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Northwestern University, which has 1,209 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which esterified estrogens is the first listed.
NCT00131924 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00131924 about?
NCT00131924 is a clinical study titled "High-Dose Esterified Estrogens in Treating Postmenopausal Women With Metastatic Breast Cancer That Has Failed Previous Hormone Therapy". RATIONALE: High doses of esterified estrogens may stop the growth of breast cancer cells that no longer respond to hormone therapy. PURPOSE: This phase II trial is studying how well high-dose esterified estrogens work in treating postmenopausal women with metastatic breast cancer that has failed pr...
What is the current status of trial NCT00131924?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 1 participants. The study started on 2004-03. Estimated completion is 2006-01.
What interventions are being tested in trial NCT00131924?
The interventions under investigation include: esterified estrogens (BIOLOGICAL).
Who is sponsoring clinical trial NCT00131924?
This trial is sponsored by Northwestern University, which has 1,209 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.